object
aim
articl
summar
pharmacolog
pharmacokinet
efficaci
daptomycin
explor
safeti
profil
discuss
current
potenti
role
antimicrobi
therapi
result
phase
iii
studi
result
suggest
differ
efficaci
toler
daptomycin
mgkg
iv
qd
vancomycin
semisynthet
penicillin
complic
skin
skinstructur
infect
anim
studi
suggest
daptomycin
may
use
treatment
endocard
daptomycin
indic
pneunionia
poorer
outcom
convent
treatnient
avail
iv
niedic
exhibit
plasnia
protein
bind
vitro
healthi
adult
human
daptoniycin
volum
distribut
ukg
plasma
elimin
halflif
hour
elimin
primarili
renal
excret
patient
reduc
renal
function
includ
receiv
hemodialysi
periton
dialysi
dose
interv
hour
dosag
adjustni
appear
necessari
mild
nioder
hepat
impairni
use
daptomycin
patient
sever
hepat
irnpairni
assess
niost
comnionli
report
advers
event
includ
constip
nausea
injectionsit
reaction
headach
diarrhea
patient
also
nionitor
regularli
skelet
niuscl
toxic
conclus
daptoniycin
may
use
complic
skin
skinstructur
infect
gramposit
pathogen
resist
convent
antimicrobi
howev
limit
data
current
avail
durat
treatment
beyond
day
dose
mgkg
qd
clin
ther
challeng
treatment
infect
due
gramposit
pathogen
develop
resist
current
avail
agent
vancomycin
tradit
use
treat
infect
caus
oxacillinresist
methicillinresist
staphylococcu
aureu
orsa
mrsa
respect
strain
reduc
suscept
vancomycin
minimum
concentr
inhibit
growth
llgmd
term
vancomycinintermedi
aureu
visa
z
appear
sinc
r
addit
clinic
case
vancomycinresist
aureu
vrsa
minimum
inhibitori
concentr
mic
llgml
unit
state
detect
sinc
increas
resist
vancomycin
among
enterococc
strain
also
grow
concern
use
newer
antimicrobi
linezolid
quinupristindalfopristin
treatment
nosocomi
infect
attribut
vancomycinresist
strain
reveal
new
resist
problem
well
linezolidresist
enterococci
appear
sinc
drug
first
use
patient
receiv
linezolid
vancomycinresist
enterococcusfaecium
vref
infect
r
addit
linezolidresist
clinic
strain
aureu
identifi
resist
linezolid
associ
use
agent
least
week
furthermor
linezolidresist
vref
lrvref
strain
also
identifi
patient
without
prior
treatment
linezolid
addit
current
estim
suggest
incid
resist
quinupristindalfopristin
e
faecium
worldwid
compar
report
unit
state
sentri
antimicrobi
surveil
program
data
year
also
found
suscept
quinupristindalfopristin
decreas
unit
state
year
clearli
chang
suscept
profil
gramposit
pathogen
escal
need
innov
drug
articl
review
pharmacolog
efficaci
safeti
daptomycin
earli
studi
investig
use
daptomycin
conduct
eli
lilli
compani
indianapoli
indiana
cubist
pharmaceut
trademark
cubicirt
cubist
pharmaceut
inc
lexington
massachusett
inc
obtain
worldwid
market
right
daptomycin
submit
investig
new
drug
applic
us
food
drug
administr
fda
decemb
daptomycin
receiv
market
approv
fda
septemb
treatment
complic
skin
skinstructur
infect
caus
suscept
gramposit
pathogen
includ
aureu
streptococcu
pyogen
streptococcu
agalactia
streptococcu
dysgalactia
subspeci
equisimili
vancomycinsuscept
enterococcu
faecali
daptomycin
use
continu
investig
ongo
trial
indic
present
review
also
discuss
potenti
place
therapi
daptomycin
first
new
class
antibiot
acid
cyclic
lipopeptid
antibiot
ndecanoyl
analog
lipopeptid
factor
one
ferment
product
complex
produc
roseosporu
daptomycin
character
cyclic
acid
anion
nucleu
arnidelink
lipophil
acid
fatti
acyl
side
chain
figur
analog
acid
core
contain
uniqu
amino
acid
eg
lkynurenin
glutamin
acid
lacton
bond
ring
antimicrobi
activ
requir
least
carbon
fatti
acyl
side
chain
longer
chain
show
greater
antimicrobi
activ
chemic
enzymat
modif
daptomycin
ie
demonstr
best
combin
vitro
antimicrobi
activ
select
gramposit
cocci
least
acut
toxic
mice
median
lethal
dose
mgkg
iv
among
structur
deriv
synthes
chemic
name
compound
daptomycin
empir
formula
molecular
weight
kda
purpos
articl
follow
review
pharmacolog
pharmacokinet
vitro
vivo
efficaci
daptomycin
explor
safeti
profil
first
agent
new
class
antimicrobi
discuss
current
potenti
role
antimicrobi
therapi
addit
inform
obtain
fda
web
site
contain
document
submit
fda
support
new
drug
applic
daptomycin
daptornycin
appear
disrupt
membran
potenti
bacteri
cell
membran
figur
bind
phospholipid
vesicl
planar
bilay
daptornycin
insert
acyl
fatti
acid
chain
bacteri
cytoplasm
membran
trigger
oligomertz
membran
protein
form
ion
channel
transmembran
pore
aggreg
structur
across
plasma
membran
although
initi
bind
occur
independ
calcium
daptomycin
requir
physiolog
concentr
calcium
mgdl
vitro
reduc
microbi
viabil
conform
chang
core
decapeptid
lacton
induc
bind
calcium
ion
increas
arnphiphat
reduc
charg
allow
daptomycin
interact
neutral
acid
membran
presenc
calcium
ion
promot
insert
daptomycin
tail
phospholipid
layer
exposur
hydrophob
surfac
facilit
penetr
oligomer
step
format
transmembran
structur
disrupt
membran
integr
result
leakag
intracellular
potassium
dissip
membran
potenti
gramposit
pathogen
antimicrobi
activ
associ
reduct
membran
potenti
rnv
rnv
independ
chang
ph
chemic
gradient
across
cell
membran
reduct
electr
potenti
disrupt
electrochem
gradientinduc
proton
motiv
forc
requir
adenosin
triphosph
synthesi
normal
play
role
activ
transport
nutrient
concentr
amino
acid
format
nucleotidelink
sugarpeptid
precursor
peptidoglycan
earli
studi
attempt
delin
mechan
action
daptomycin
suggest
may
inhibit
biosynthesi
lipoteicho
acid
one
constitu
plasma
membran
sr
peptidoglycan
compon
gramposit
bacteria
studi
e
faecium
protoplast
lack
peptidoglycan
layer
support
hypothesi
daptomycin
inhibit
product
lipoteicho
acid
primari
mechan
action
secondari
result
inhibit
peptidoglycan
synthesi
although
hypothesi
support
accumul
lipoteicho
acid
precursor
detect
use
thinlay
recent
studi
reveal
daptomycin
remain
bactericid
even
absenc
ongo
lipoteicho
acid
synthesi
regardless
mechan
action
scan
electron
microscopi
reveal
induct
abnorm
featur
eg
antlerlik
protrus
ghost
bleb
deep
weblik
fissur
structur
eg
filament
growth
linear
ceil
miniatur
cell
cell
surfac
daptomycin
treatment
morpholog
chang
believ
associ
product
defect
cell
wall
materi
appear
occur
independ
calciummedi
intracellular
penetr
daptomycin
target
site
daptomycin
pharmacokinet
studi
vitro
anim
healthi
human
adult
also
case
report
describ
daptomycin
pharmacokinet
adult
infect
iv
administr
daptomydn
undergo
distribut
model
elimin
primarili
renal
excret
valu
pharmacokinet
paramet
indic
mean
mean
sd
valu
unless
otherwis
indic
pharmacokinet
paramet
dose
mgkg
everi
hour
summar
tabl
pharmacokinet
studi
vitro
show
daptomycin
exhibit
plasma
protein
bind
mean
ad
whole
serum
concentr
serum
sampl
healthi
human
subject
show
plasma
protein
bind
particular
daptomycin
bind
albumin
expect
acid
cornpound
daptomycin
may
also
bind
alphakacid
glycoprotdn
vitro
concentr
lagrnl
pgrnl
daptomycin
show
detect
bind
alphalacid
glycopeptid
base
mic
pgml
total
bound
unbound
drug
aureu
one
enterococcu
strain
describ
woodworth
et
al
pharmacokinet
studi
suggest
daptomydn
administ
clinic
dose
least
mgkg
high
degre
protein
bind
may
account
therapeut
failur
observ
earli
clinic
studi
conduct
eli
lilli
compani
cite
lee
et
serum
concentr
unbound
drug
may
suffici
exceed
mic
inhibit
bacteri
growth
exampl
mic
total
ie
mice
daptornycin
show
plasma
protein
bind
linear
increas
dose
cm
x
auc
increas
dose
dose
linear
pharmacokireti
observ
even
dose
associ
peak
concentr
llgml
auc
llghml
daptomycin
mgkg
bid
rabbit
yield
steadyst
cm
x
tgml
similar
human
receiv
mgkg
iv
bid
trough
concentr
llgml
hour
daptomycin
mgkg
qd
rat
achiev
similar
blood
concentr
human
dose
rngkg
qd
respect
mean
peak
concentr
rat
hour
llgml
respect
concentr
undetect
hour
model
inflammatori
methicillinsensit
cmreu
mrsa
ie
infect
rabbit
treat
daptomycin
mgkg
mean
peak
concentr
daptomycin
fibrin
clot
core
lower
concentr
took
hour
longer
achiev
compar
peak
concentr
peripheri
clot
auc
clot
also
significantli
higher
peripheri
core
dose
test
p
mean
sd
auc
serum
also
greater
fibrin
clot
daptomycin
thu
limit
diffus
daptornycin
fibrin
clot
veget
endocard
may
limit
treatment
success
among
guinea
pig
infect
streptococcu
epdermid
tissuecag
model
devicerel
infect
daptomycin
msk
bid
produc
cm
x
tgml
cram
tgml
day
treatment
administr
singl
dose
daptomycin
clinic
studi
dose
eg
mgkg
appar
volum
distribut
vd
human
rang
ukg
may
affect
high
degre
protein
bind
larg
molecular
size
daptomycin
exhibit
linear
accumul
dose
mgkg
pharmacokinet
distribut
consist
model
complet
distribut
phase
occur
hour
administr
daptomycin
overal
daptomycin
show
limit
total
bodi
clearanc
rate
mlmin
per
kg
dose
mgkg
via
iv
infus
renal
clearanc
account
total
system
clearanc
daptornycin
pharmacokinet
also
studi
doubleblind
multipledos
doseescal
qd
regimen
among
healthi
male
femal
adult
treat
daptomycin
day
treatment
dose
mgkg
per
dose
daptornycin
show
linear
pharmacokinet
nonlinear
pharmacokinet
dose
increas
mgkg
highest
dose
studi
date
exampl
day
treatment
doubl
dose
mgkg
mgkg
result
increas
auc
c
rather
predict
increas
auc
cm
mean
sd
auc
tlgtfml
vs
tlgtfml
mean
sd
cmax
lgml
vs
lgml
dose
tx
estim
hour
v
calcul
lkg
system
clearanc
occur
rate
mlmin
per
kilogram
report
mlh
per
kg
dose
excret
intact
urin
healthi
male
volunt
year
old
within
ideal
bodi
weight
treat
singl
dose
hctrplabel
daptomycin
mgkg
via
iv
dose
label
compound
ie
daptomycin
metabolit
recov
urin
fecal
sampl
within
first
day
approxim
radiolabel
daptomycin
recov
urin
fece
day
wherea
trace
amount
label
compound
recov
breath
saliva
daptomydn
radiolabel
compound
identifi
plasma
label
compound
recov
urin
daptomydn
suggest
daptomycin
may
undergo
renal
metabol
furthermor
comparison
pharmacokinet
radiolabel
hccompound
mgkg
iv
infus
unlabel
daptornycin
rngkg
similar
degre
accumul
extent
exposur
mean
sdi
x
studi
daptornycin
pharmacokinet
conduct
patient
infect
model
canthadrininduc
inflamm
penetr
daptornycin
inflammatori
fuid
investig
daptomycin
mgkg
iv
penetr
inflammatori
fluid
mean
sd
cm
x
lagml
hour
within
hour
mean
sd
auc
tghml
halflif
daptomydn
inflammatori
fluid
highli
variabl
rang
hour
mean
time
hour
comparison
volunt
treat
daptomydn
mgkg
iv
without
inflamm
show
mean
sd
auc
tlgtfml
thour
mean
sd
cm
x
tlgml
hour
degre
accumul
similar
rat
inflammatori
fluid
mgkg
inflammatori
fluid
rat
daptomydn
produc
c
x
lgml
hour
auc
tghml
period
slightli
higher
auc
report
inflammatori
fluid
human
volunt
one
case
report
hivposit
male
receiv
daptomycin
mgkg
qd
day
cellul
thrombophleb
caus
group
betahemolyt
streptococci
appar
v
estim
ukg
elimin
determin
hour
first
dose
hour
fifth
dose
daptomycin
clear
rate
mlmin
first
fifth
dose
respect
first
dose
dose
renal
excret
unchang
healthi
volunt
histor
data
patient
given
regimen
daptornycin
although
differ
pharmacokinet
paramet
detect
patient
sampl
observ
differ
may
associ
rel
low
serum
alburnin
mean
rngdl
rang
rngdl
among
ivda
use
data
collect
particip
clinic
trial
dvorchik
et
al
evalu
sourc
interindividu
variabl
analysi
daptomycin
popul
pharmacokinet
patient
receiv
daptomycin
mgkg
qd
day
overal
model
confirm
daptomycin
distribut
clearanc
follow
model
firstord
elimin
linear
relationship
determin
v
peripher
compart
intercompartment
clearanc
bodi
weight
support
dose
daptomycin
milligramperkilogram
basi
renal
function
sex
bodi
temperatur
factor
found
affect
daptomycin
kinet
particular
renal
function
singl
import
factor
reduc
variabl
bayesian
estim
pharmacokinet
paramet
patient
similar
degre
renal
function
femal
patient
show
clearanc
rate
exhibit
male
patient
although
recommend
dosag
adjust
addit
although
bodi
temperatur
cite
potenti
sourc
variabl
author
provid
statist
detail
impact
caution
reader
interpret
result
subject
bodi
temperatur
factor
found
contribut
daptomycin
clearanc
includ
presenc
comorbid
diseas
ie
diabet
melfitu
ascit
edema
hypertens
heart
failur
concomit
use
medic
activ
secret
renal
tubul
highli
protein
bound
date
abstract
publish
report
describ
pharmacokinet
daptomycin
patient
vari
degre
renal
function
patient
categor
accord
creatinin
clearanc
level
endstag
renal
diseas
requir
hemodialysi
periton
dialysi
result
pharmacokinet
studi
summar
tabl
ii
smallscal
studi
n
report
sica
et
al
statist
signific
differ
although
level
signific
report
found
plasma
clearanc
patient
mlmin
receiv
dialysi
compar
group
mumin
compar
auc
patient
mldmin
auc
ratio
patient
mlmin
patient
receiv
hemodialysi
patient
receiv
periton
dialysi
thu
accord
fda
recommend
evalu
pharmacokinet
patient
reduc
renal
function
fie
dosag
adjust
requir
auc
ratio
c
x
ratio
comparison
group
author
suggest
daptomycin
dose
adjust
patient
rnumm
similar
result
also
report
anoth
analysi
use
differ
definit
renal
insuffici
n
reduc
plasma
clearanc
prolong
found
among
patient
sever
renal
diseas
ie
mumin
receiv
hemodialysi
although
level
statist
signific
report
base
daptomycin
dosag
adjust
patient
mijmin
popul
pharmacokinet
model
incorpor
data
particip
daptomycin
time
longer
patient
mijmin
time
longer
studi
tp
versu
patient
wh
crci
mlmin
tp
versu
patient
wkh
crci
mlmin
compar
wkh
patient
crci
mlmin
iistatist
differ
although
level
signific
defin
studi
signific
differ
group
crci
mlmin
level
signific
defn
studi
report
receiv
dialysi
among
murnin
auc
valu
also
greater
respect
tabl
ii
although
auc
mean
also
differ
subject
rnumin
mumin
differ
determin
studi
author
clinic
insignific
thu
recommend
previous
adjust
daptomycin
dose
consid
patient
mlmin
singledos
paralleldesign
matchedcontrol
bodi
weight
age
sex
studi
pharmacokinet
daptomycin
compar
patient
rooder
impair
hepat
function
child
ugh
class
b
n
male
subject
versu
healthi
volunt
n
male
subject
el
particip
receiv
daptomycin
mgkg
iv
minut
signific
differ
pharmacokinet
paramet
found
hepat
impair
healthi
subject
mean
cm
x
pgml
pgml
respect
mean
hour
respect
mean
auc
respect
mean
v
steadi
state
iag
group
differ
degre
protein
bind
fraction
dose
excret
urin
rate
urinari
clearanc
base
studi
dosag
daptomycin
recommend
patient
wlth
moder
hepat
impair
comparison
pharmacokinet
conduct
among
healthi
adult
age
year
adult
age
year
result
show
total
clearanc
daptomycin
reduc
wherea
mean
auc
c
elimin
increas
respect
among
older
patient
ie
age
year
receiv
singl
dose
versu
younger
adult
ie
age
year
p
older
patient
group
show
mean
urinari
fraction
excret
wherea
younger
group
show
mean
urinari
fraction
excret
statist
signific
differ
observ
extent
exposur
older
patient
show
higher
accumul
mean
sd
auc
time
infin
tghml
vs
tghml
p
may
attribut
reduc
renal
function
associ
age
differ
observ
group
ie
mijmin
older
patient
vs
mumin
younger
patient
p
rate
advers
reaction
similar
older
younger
patient
group
overal
daptomycin
pharmacokinet
may
affect
renal
function
rather
age
alon
suggest
dosag
reduct
base
age
sole
among
moder
obes
patient
bodi
mass
index
bmi
mean
cmx
auc
greater
respect
among
match
nonobes
control
receiv
singl
dose
daptomycin
mgkg
base
total
bodi
weight
addit
mean
total
renal
clearanc
greater
respect
extrem
obes
patient
bmi
mean
cm
x
auc
increas
respect
versu
nonobes
adult
patient
howev
mean
total
renal
clearanc
greater
respect
controlsp
studi
conduct
examin
differ
pharmacokinet
accord
race
sex
addit
studi
conduct
pregnant
lactat
women
numer
studi
delin
vitro
antibacteri
activ
daptomycin
publish
daptomycin
bind
molecular
target
calciumdepend
manner
studi
calcium
concentr
test
medium
muellerhinton
broth
use
microdilut
suscept
test
adjust
mimic
physiolog
level
human
serum
ie
ragl
perform
accord
guidelin
set
nation
committe
clinic
laboratori
standard
nccl
select
review
date
daptomycin
suscept
mic
breakpoint
establish
nccl
base
vitro
spectrum
activ
vivo
pharmacodynam
studi
clinic
failur
analys
daptomycin
fda
propos
suscept
breakpoint
mic
lagml
aureu
streptococcu
speci
streptococcu
preumorta
suscept
breakpoint
mic
tgrnl
vancomycinsuscept
efaecaz
suscept
interpret
criteria
organ
defin
daptomycin
test
vitro
wide
rang
clinic
import
gramposit
bacteria
includ
aureu
coagulaseneg
staphylococci
e
jaecal
e
faecium
pneumona
pyogen
agalactta
viridan
group
streptococci
group
b
c
streptococci
critchley
et
al
report
vitro
activ
daptomycin
total
isol
gramposit
pathogen
collect
patient
specimen
regardless
resist
pattern
staphylococc
streptococc
isol
suscept
daptomycin
mic
llgml
except
unspecifi
number
isol
vancomycinsensit
e
aecium
non
aecium
non
aecali
enterococcu
speci
inhibit
pgml
mean
bgml
rang
pgml
isol
enterococci
suscept
daptomycin
mic
p
gml
r
similar
result
report
investigatorsp
n
incid
elev
daptomydn
mic
gramposit
bacteria
low
exampl
studi
conduct
strdt
et
al
n
isol
aureu
isol
coagulaseneg
staphylococci
mic
pgml
almost
isol
enterococci
inhibit
daptomycin
tgml
appear
daptomycin
potent
vitro
activ
wide
rang
clinic
import
gramposit
pathogen
daptomycin
also
demonstr
vitro
activ
emerg
multidrugresist
gramposit
pathogen
includ
visa
mic
pgml
vrsa
mic
pgml
howe
et
al
studi
vitro
activ
daptomycin
strain
visa
collect
worldwid
unit
state
japan
strain
test
suscept
daptomycin
mic
rang
llgml
strain
vrsa
strain
mic
llgml
isol
hershey
medic
center
hershey
pennsylvania
heel
wound
male
patient
report
suscept
daptomycin
mic
pgrnl
vitro
activ
daptomycin
select
gramposit
pathogen
summar
tabl
tabl
studi
indic
mic
daptomycin
greatli
affect
resist
pattern
suscept
pathogen
mic
within
doubl
dilut
may
due
uniqu
mechan
action
daptomycin
target
bacteri
membran
daptomycin
may
import
role
treatment
infect
caus
multidrugresist
pathogen
howev
opinion
vitro
activ
antimicrobi
agent
necessarili
translat
clinic
use
activ
drug
also
influenc
factor
degre
vivo
protein
bind
abil
reach
therapeut
concentr
infect
site
inoculum
eflect
vitro
pharmacokinet
model
bactericid
activ
daptomycin
test
vree
mean
time
requir
kill
increas
hour
hour
presenc
physiolog
concentr
albumin
gdl
test
medium
jan
et
al
studi
bactericid
activ
daptomycin
lrvrefvref
report
increas
mic
test
medium
supplement
albumin
concentr
gde
clinic
failur
daptomycin
earlier
studi
subject
administ
daptomycin
mgkg
daili
current
fdaapprov
dosag
complic
skin
skinstructur
infect
treatment
bacteremia
endocard
could
explain
partli
low
level
free
activ
drug
clinic
relev
protein
bind
daptomycin
therapi
remain
delin
daptomycin
possess
postantibiot
effect
ie
length
time
bacteri
growth
suppress
brief
exposur
antibiot
gramposit
bacteria
includ
aureu
hour
coagulaseneg
staphylococci
h
hour
pneumonia
hour
efaecali
hour
safdar
et
al
studi
vivo
pharrnacodynarn
activ
daptornycin
neutropen
rnurin
thigh
infect
model
consist
concentrationdepend
bactericid
activ
daptomycin
aucmic
ratio
peak
concentrationm
ratio
peakmic
strong
predictor
vivo
efficaci
r
respect
efficaci
relat
period
time
serum
concentr
daptomycin
mic
r
howev
find
pharmacodynam
studi
suggest
aucmic
ratio
better
pharmacodynam
paramet
r
sr
peakmic
ratio
predict
antibacteri
efficaci
daptomycin
sever
investig
assess
vitro
activ
daptomycin
combin
ampicillin
aztreonam
cefepirn
ceftriaxon
fosfomycin
gentarnicin
imipenem
oxacillin
rifampin
tobramycin
multipl
strain
aureu
coagulaseneg
staphylococci
e
jaecali
enterococci
ssssg
overal
interact
daptomycin
antimicrobi
agent
synergist
addit
indiffer
antagon
observ
therefor
daptomycin
may
combin
antibiot
treatment
infect
due
gramposit
pathogen
although
studi
need
confirm
vivo
efficaci
combin
develop
spontan
resist
daptomycin
rare
resist
rate
aureu
epidermidt
ejaecali
efaecium
pneumonia
serial
passag
n
suscept
strain
aureu
strain
druggradi
plate
result
mutant
strain
increas
mic
eleven
resist
aureu
mutant
strain
mic
higher
origin
isol
obtain
chemic
rnutagenesi
nmethylnnitronnitrosoguanidin
note
none
mutant
isol
exhibit
crossresist
vancomycin
ampicillin
emerg
resist
note
occas
phase
iviii
clinic
trial
involv
aureu
strain
mic
mgml
patient
endocard
eaecal
strain
mic
mgml
patient
infect
decubitu
ulcer
mechan
spontan
resist
daptomydn
may
multifactori
remain
elucid
date
report
crossresist
daptomydn
antimicrobi
agent
publish
daptomycin
efficaci
studi
rat
rabbit
hamster
mice
varieti
infect
model
although
major
preclin
anim
studi
conduct
endocard
model
efficaci
also
examin
anim
model
pneumonia
lot
os
bacteremia
osteomyel
intraabdomin
infect
skin
skinstructur
infect
pyelonephr
use
daptomycin
prevent
aminoglycosideinduc
nephropathi
also
examin
anim
model
rel
efficaci
daptomycin
compar
regimen
anim
studi
summar
tabl
v
detail
regard
experiment
method
statist
analys
origin
citat
review
statist
signific
result
report
treatment
endocard
mix
result
found
daptomycin
appear
effect
salin
treatment
use
antibiot
regimen
other
similarli
treatment
pneumonia
daptomycin
found
yield
better
surviv
rate
salin
treatment
strain
exhibit
inferior
activ
compar
vancomycin
studi
despit
dosedepend
bactericid
activ
note
treatment
pathogen
studi
daptomycin
use
bacterernia
daptomycin
significantli
increas
surviv
rate
steril
organ
cultur
compar
control
vancomycin
dose
mice
l
limit
success
also
note
erad
osteornyel
daptomycin
vancornycin
although
either
treatment
regimen
may
produc
better
result
treatment
among
control
note
daptomycin
detect
noninfect
bone
reach
concentr
llgml
infect
bone
p
concentr
numer
lower
serum
concentr
hypothes
higher
ioniz
calcium
level
site
infect
may
activ
daptomycin
treatment
osteomyel
treatment
intraabdomin
infect
daptomycin
appear
prolong
surviv
onset
clostridmm
difficil
pseudomembran
coliti
compar
treatment
hamster
howev
prolong
occur
durat
treatment
vancomycin
hamster
anim
studi
skin
skinstructur
infect
daptomycin
effect
untreat
control
oxacillin
vancornycin
daptomycin
may
also
use
treatment
ventricul
administ
singl
intraventricular
dose
treatment
pyelonephr
daptomycin
efficaci
vancomycin
sever
day
treatment
show
greater
efficaci
bid
regimen
qd
regimen
studi
regardless
addit
gentamicin
howev
ampicillin
plu
gentamicin
appear
lower
bacteri
count
daptomycinbas
regimen
addit
steril
kidney
ss
studi
also
suggest
daptomycin
may
play
role
prevent
aminoglycosidetablev
summari
statist
signific
differ
daptomycin
compar
treatment
regimen
anim
studi
daptorn
induc
nephrotox
interf
interact
arninoglycosid
phosphatidylinositol
receptor
cell
membran
without
daptomycin
pinocytosi
aminoglycosid
cytoplasm
vacuol
fusion
vacuol
lysosom
result
format
myeloid
bodi
burst
lysosom
follow
tubular
cell
necrosi
impair
renal
function
howev
differ
pattern
f
accumul
daptomycin
myeloid
bodi
lysosom
administ
without
tobramycin
support
specul
mechan
daptomycin
interfer
arninoglycosid
bind
membran
renal
proxim
tubular
ceil
unfortun
date
publish
studi
describ
efticaci
daptomycin
treatment
infect
human
subject
sever
smallscal
phase
ii
studi
initi
eli
lilli
compani
openlabel
trial
year
includ
mgkg
load
dose
follow
mgkg
bid
daptomycin
mgkg
qd
treatment
complic
skin
skinstructur
infect
bgbmcavam
load
dose
mgkg
follow
mgkg
bid
treatment
cutoutbid
bacteremia
endocard
howev
studi
termin
earli
due
advers
event
ae
slow
enrol
major
inform
discuss
section
avail
abstract
poster
form
document
submit
fda
drug
approv
l
z
base
evalu
safeti
data
earlier
preclin
clinic
studi
cubist
pharmaceut
inc
modifi
recommend
administr
schedul
daptomycin
divid
daili
dose
qd
dose
regimen
b
result
multicent
multin
investigatorblind
random
phase
iii
studi
skin
skinstructur
infect
conduct
adult
age
year
march
decemb
combin
report
arbeit
al
ls
data
studi
collect
site
unit
state
south
africa
data
collect
site
europ
south
africa
australia
israel
studi
design
use
studi
patient
includ
complic
skin
skinstructur
infect
caus
known
suspect
gramposit
bacteri
pathogen
requir
hospit
iv
antibiot
hour
type
infect
includ
major
abscess
infect
ulcer
wound
infect
l
r
patient
exclud
superfici
skin
infect
multipl
infect
ulcer
differ
site
gangren
perirect
abscess
thirddegre
burn
requir
cur
surgeri
bacteremia
studi
entri
life
expect
month
infect
due
primarili
gramneg
pathogen
pathogen
show
resist
daptomycin
vancomydn
purpos
studi
lib
compar
efficaci
daptomycin
mgkg
iv
qd
versu
compar
regimen
consist
penidllinaseresist
penidllin
ie
cloxadllin
nakillin
oxadllin
flucloxacillin
gd
iv
equal
divid
dose
vancomycin
g
iv
qd
patient
recruit
studi
first
randomli
assign
cornpar
group
either
penicillinaseresist
penicillin
vancomycin
random
receiv
day
daptomycin
compar
treatment
accord
earlier
assign
chang
oral
antibiot
allow
patient
receiv
least
day
iv
antibiot
show
clinic
improv
evalu
investig
blind
treatment
assign
found
infect
pathogen
suscept
oral
antibiot
compel
reason
stop
iv
antibiot
eg
discharg
hospit
primari
end
point
studi
testofcur
evalu
conduct
day
last
dose
antibiot
site
infect
inspect
investig
blind
treatment
assign
goal
studi
demonstr
noninferorti
defin
upper
limit
ci
differ
daptomycin
cornpar
treatment
ie
cornpar
success
rate
minu
daptomycin
success
rate
clinic
success
defin
resolut
sign
symptom
infect
suftici
discontinu
antibiot
therapi
patient
also
evalu
clinic
relaps
recurr
day
complet
treatment
inadequ
respons
treatment
followup
period
classifi
clinic
failur
statist
comparison
summar
conduct
intenttotreat
itt
group
includ
patient
receiv
dose
studi
medic
clinic
evalu
group
consist
patient
itt
group
met
inclus
exclus
criteria
recruit
present
confound
factor
eg
use
antibiot
intercurr
infect
overal
patient
includ
itt
analysi
patient
tile
clinic
evalu
popul
efficaci
safeti
analys
differ
baselin
characterist
daptomycin
compar
group
n
n
respect
found
age
race
sex
comorbid
condit
ie
diabet
mellitu
peripher
vascular
diseas
immunocompromis
statu
baselin
diagnosi
approxim
patient
group
complet
therapi
therapeut
failur
cite
common
reason
discontinu
therapi
sixti
percent
comparatortr
patient
receiv
penicillinaseresist
penicillin
addit
aztreonam
andor
metronidazol
administ
patient
daptomycintr
group
patient
cornparatortr
group
signific
differ
clinic
success
rate
seen
daptomycin
cornpar
group
itt
group
vs
ci
p
ns
clinic
evalu
group
vs
ci
p
ns
itt
group
patient
switch
iv
oral
therapi
although
choic
stepdown
therapi
detail
among
patient
receiv
iv
antibiot
daptomycintr
patient
receiv
day
therapi
compar
patient
compar
group
p
suggest
shorter
durat
iv
treatment
may
yield
similar
treatment
efficaci
addit
differ
rate
clinic
relaps
recurr
detect
daptomydn
compar
treatment
group
ci
safeti
analys
ae
classifi
mild
moder
mark
sever
accord
world
health
organ
toxic
grade
scale
fifteen
patient
daptomycin
group
patient
cornpar
group
discontinu
treatment
due
ae
although
major
ae
relat
studi
medic
daptomycintr
patient
comparatortr
patient
experienc
treatmentrel
ag
ag
report
patient
follow
daptomydn
constip
nausea
injectionsit
reaction
headach
diarrhea
vancomycin
nausea
constip
injectionsit
reaction
semisynthet
penidllin
headach
injectionsit
reaction
least
sever
ae
seen
daptomycintr
comparatortr
patient
overal
type
dual
infect
includ
patient
nonhemolyt
streptococc
strain
nonhemolyt
streptococci
enterococci
nonhemolyt
streptococci
anaerob
infect
patient
enterococc
strain
treatment
regimen
consist
daptomycin
standard
therapi
semisynthet
penicillin
vancomycin
aztreonam
metronidazol
could
ad
although
detail
antimicrobi
treatment
includ
abstract
overal
success
rate
dual
infect
aureu
hemolyt
streptococci
lower
dual
infect
vs
p
fisher
exact
test
regardless
dual
infect
statu
kaplanmei
analys
also
found
aureu
infect
persist
longer
patient
diabet
mellitu
without
show
clearanc
vs
day
p
differ
rate
clearanc
daptomycin
standard
treatment
group
vs
day
respect
p
report
conclus
regard
efficaci
daptomycin
standard
therapi
could
made
subset
patientsl
separ
abstract
describ
resolut
clinic
sign
subset
patient
patient
evalu
sever
clinic
sign
skin
soft
tissu
infect
includ
tender
indur
purul
sign
assign
score
none
present
mild
moder
sever
composit
score
determin
patient
itt
analysi
daptomycin
cornpar
group
show
clinic
efficaci
baselin
group
median
score
day
treatment
daptomycin
recipi
show
median
decreas
score
wherea
compar
group
show
decreas
p
median
durat
treatment
daptomycin
also
shorter
vs
day
p
suggest
similar
efficaci
may
achiev
rapidli
bacteremia
two
ongo
phase
ii
openlabel
clinic
trial
evalu
efficaci
safeti
daptomycin
ragk
qd
mgkg
qd
ragk
bid
treatmerit
bacteremia
way
report
abstract
year
patient
treat
daptomycin
mgkg
qd
show
clinic
respons
although
defin
abstract
compar
patient
treat
vancomycin
g
bid
differ
ae
profil
found
group
detail
regard
number
particip
specif
detail
type
ae
report
time
public
abstract
instead
studi
detail
provid
record
submit
fda
show
studi
patient
receiv
daptomycin
mgkg
qd
patient
receiv
daptomycin
mgkg
qd
patient
receiv
daptomycin
mgkg
bid
load
dose
mgkg
cornpar
group
consist
patient
receiv
standard
therapi
vancomycin
g
bid
nafcillin
oxacillin
g
daili
equal
divid
dose
patient
confirm
presum
gramposit
bacteremia
studi
lr
daptomycin
administ
openlabel
noncompar
multicent
trial
use
dose
regimen
bacteremia
mgkg
qd
mgkg
qd
mgkg
bid
load
dose
patient
indic
treatment
gramposit
infect
also
includ
studi
complic
skin
skinstructur
infect
mgkg
qd
lower
respiratori
tract
infect
mgkg
qd
intraabdomin
infect
mgkg
qd
complic
urinari
tract
infect
due
vancomycinresist
otherwis
refractorytotreat
pathogen
mgkg
qd
patient
receiv
treatment
day
trial
termin
earli
due
slow
enrol
lr
two
case
bacteremia
patient
undergo
neutropen
bone
marrow
transplant
treat
daptomydn
inadequ
treatment
vancomycin
first
case
woman
recurr
hodgkin
lymphoma
develop
bacteremia
chemotherapi
transplant
despit
prophylact
regimen
ciprofloxacin
sulfamethoxazoletrimethoprim
acyclovir
imipenem
vancomycin
start
imipenem
chang
cefepim
respons
rash
amphotericin
ad
regimen
patient
develop
grade
graftversushost
diseas
treat
hydrocortison
subsequ
septic
shock
blood
cultur
posit
leuconostoc
meseneroid
resist
vancomycin
mic
pgrnl
isol
sensit
daptomycin
mic
pgml
daptomycin
initi
bolu
follow
mgkg
q
h
adjust
mumin
day
increas
mgkg
qd
improv
renal
function
total
day
treatment
patient
discharg
day
side
effect
daptomydn
report
second
case
also
involv
l
man
relaps
acut
myeloblast
leukemia
complic
linerel
bacteremia
penicillininduc
rash
peripher
neuropathi
renal
insuffici
wait
month
allogeni
bone
marrow
transplant
eight
day
relaps
patient
found
bacteremia
l
meseneroid
suscept
daptomycin
treatment
start
mgkg
qd
continu
lumbar
punctur
day
later
reveal
presenc
leukem
mening
epidermtdi
cerebrospin
fluid
daptomycin
discontinu
vancomycin
start
bacteremia
resum
daptomycin
continu
week
one
month
resolut
infect
patient
die
complic
relat
leukemia
treatment
catheterrel
bacteremia
due
vancomydnresist
nosocomi
pathogen
overal
daptomydn
safe
effect
use
daptomycin
investig
treatment
moder
sever
communityacquir
pneumonia
cap
due
pneumonia
studi
phase
ii
random
rnulticent
multin
doubleblind
paralleltr
activecontrol
trial
compar
efficaci
safeti
daptomycin
mgkg
qd
versu
ceftriaxon
g
qd
compar
arm
aztreonam
could
ad
gramneg
coverag
accord
studi
investig
anticip
treatment
durat
day
testofcur
assess
day
last
dose
studi
medic
men
women
age
year
pneumonia
caus
known
suspect
gramposit
bacteria
requir
hospit
iv
antibiot
day
consid
trial
studi
conduct
center
unit
state
europ
canada
australia
south
america
new
zealand
patient
random
daptomycin
group
patient
cornpar
group
howev
daptomycin
treatment
fail
meet
predetermin
criterion
noninferior
differ
clinic
success
daptomycin
ceftriaxon
upper
ci
clinic
success
base
result
studi
termin
patient
receiv
daptomycin
patient
receiv
ceftriaxon
among
patient
receiv
studi
medic
studi
daptomydn
group
ceftriaxon
group
receiv
medic
day
overal
patient
receiv
daptomydn
treatment
prematur
discontinu
treatment
vs
patient
group
cite
clinic
failur
reason
discontinu
therapi
vs
respect
thu
daptomycin
indic
treatment
pneumonia
specif
note
packag
insert
limit
penetr
accumul
daptomycin
alveolar
site
infect
may
contribut
lack
clinic
efficaci
treatment
pneumonia
addit
studi
includ
patient
complic
urinari
tract
infect
studi
plan
openlabel
phase
iii
comparison
daptomycin
mgkg
qd
versu
dprofloxadn
mgllz
arm
studi
recruit
patient
major
patient
receiv
treatment
day
howev
studi
termin
earli
due
slow
enrol
earli
studi
aureu
endocard
bsbmcavam
compar
efficaci
safeti
daptomycin
mgkg
bid
versu
compar
treatment
eg
nafcillin
gentamicin
lit
studi
patient
daptomycin
group
compar
group
die
caus
death
attribut
medic
administ
eg
abscess
cardiac
arrest
multiorgan
failur
respiratori
failur
gastric
aspir
howev
hypothes
despit
adequ
treatment
staphylococc
bacterernia
daptornycin
mgkg
bid
dose
may
effect
treatment
endocard
due
pathogen
subsequ
studi
propos
use
daptornycin
mgkg
qd
due
concern
regard
subtherapeut
respons
potenti
consequ
studi
investig
sought
receiv
fda
approv
recruit
patient
rightsid
endocard
l
r
result
studi
avail
time
manuscript
prepar
safeti
data
submit
fda
approv
daptomycin
consist
data
use
agent
particip
phase
studi
phase
ii
studi
phase
iii
studi
lit
section
present
articl
review
safeti
data
preclin
clinic
studi
subsequ
recomrnend
dose
daptornycm
addit
discuss
occurr
daptornycinrel
seriou
ae
need
discontinu
daptornycin
clinic
studi
emphasi
result
phase
iii
trial
support
use
daptornycin
fdaapprov
indic
treatment
complic
skin
skinstructur
infect
toxicolog
report
file
lilli
research
laboratori
indianapoli
indiana
summar
oleson
et
al
particular
concern
emerg
skelet
muscl
toxic
earli
anim
human
studi
result
pharmacokinet
studi
dog
compar
daptomycin
mgkg
singl
daili
dose
divid
daili
dose
suggest
muscl
toxic
may
relat
dose
interv
rather
c
x
extent
accumul
daptornycin
rngkg
qd
yield
higher
mean
sd
cm
x
total
daili
dose
administ
tit
tlgml
vs
tlgml
comparison
mgkg
qd
yield
mean
sd
c
x
microscopi
minim
degener
regener
myofib
observ
evid
necrosi
cell
lysi
fibrosi
statist
signific
differ
incid
myofib
lesion
found
mgkg
singl
daili
dose
divid
doseslb
instead
minim
nonsuppuratir
inflamm
secondari
skelet
muscl
degener
seen
base
anim
studi
show
higher
risk
skelet
muscl
toxic
total
daili
dose
divid
smaller
fraction
administ
singl
daili
dose
despit
greater
cm
x
investig
hypothes
increas
durat
dose
daptomycin
may
allow
repair
effect
skelet
muscl
progress
toxic
detect
qd
administr
month
lack
fibrosi
cell
lysi
even
day
treatment
suggest
daptomycin
caus
leakag
cpk
myofib
secondari
membran
perturb
daptomycininduc
myopathi
appear
specif
skelet
muscl
also
appear
nonprogress
readili
revers
natur
result
safeti
analys
dog
extrapol
human
suggest
daptomycin
administ
qd
regimen
reduc
potenti
skelet
muscl
phase
doseescal
trial
particip
receiv
daptomycin
dose
mgkg
bid
experienc
acut
increas
cpk
time
upper
limit
normal
ie
peak
cpk
valu
ul
particip
muscl
weak
myalgia
muscl
effect
revers
discontinu
daptomycin
three
subject
clinic
pharmacolog
studi
also
discontinu
particip
due
drugrel
asymptomat
elev
cpk
maximum
valu
ul
day
daptomycin
mgkg
qd
respect
ul
dose
daptomycin
load
dose
mgkg
follow
mgkg
qd
patient
also
present
mm
dimer
muscl
isozym
pattern
llz
elev
cpk
resolv
within
week
discontinu
daptomycin
phase
ii
studi
patient
also
discontinu
daptomycin
increas
cpk
occur
seven
patient
phase
iii
studi
treatment
cap
also
show
ae
affect
musculoskelet
connect
tissu
system
howev
later
pharmacokinet
studi
use
daptomycin
mgkg
everi
hour
transient
increas
cpk
time
upper
limit
normal
observ
particip
day
associ
muscl
symptom
one
subject
continu
receiv
mgkg
qd
day
without
increas
cpk
preliminari
evalu
incid
skelet
muscl
effect
associ
daptomycin
treatment
mgkg
qd
day
among
patient
phase
iii
trial
describ
arbeit
et
al
present
poster
form
knapp
et
ae
elev
serum
cpk
monitor
throughout
studi
baselin
level
cpk
ul
seen
patient
treat
daptomycin
patient
treat
semisynthet
penicillin
vancomycin
ie
comparatot
group
approxim
elev
resolv
antimicrobi
treatment
suggest
elev
associ
infect
transient
elev
cpk
occur
daptomycintr
comparatortr
patient
particularli
associ
adjunct
surgeri
intramuscular
inject
resolv
even
continu
antimicrobi
treatment
sign
symptom
skelet
muscl
damag
eg
myalgia
weak
observ
respect
howev
skelet
muscl
effect
associ
elev
cpk
resolv
continu
treatment
patient
daptomycin
group
appear
show
rise
cpk
accompani
muscl
pain
weak
may
associ
drug
day
daptomycin
cpk
concentr
peak
ul
discontinu
drug
cpk
muscl
symptom
resolv
thu
skelet
muscl
toxic
appear
common
side
effect
among
patient
receiv
daptomycin
mgkg
qd
treatment
complic
skin
skinstructur
infect
despit
chang
associ
marker
skelet
muscl
toxic
phase
studi
suggest
cardiac
tissu
appear
target
daptomycinassoci
muscl
toxic
lz
preclin
studi
vitro
concentr
daptomycin
higher
c
lx
expect
dose
daptomycin
mgkg
qd
affect
cardiac
muscl
function
exposur
daptomycin
month
show
histopatholog
condit
cardiac
muscl
function
dog
moreov
human
subject
expos
daptomycin
mgkg
qd
day
show
cardiac
chang
electrocardiogram
thu
daptomycinassoci
muscl
toxic
appear
involv
cardiac
tissu
addit
discontinu
studi
medic
due
skelet
muscl
toxic
daptomycin
use
also
associ
case
neuropathi
clinic
studi
one
patient
studi
bsbewavah
show
reduct
nerv
conduct
veloc
ncv
amplitud
receiv
lrag
dose
daptomycin
studi
halt
intend
particip
recruit
studi
patient
also
discontinu
daptomycin
treatment
secondari
neuropathi
dose
use
phase
ii
studi
daptomycin
load
dose
follow
mgkg
bid
second
patient
notic
tingl
foot
last
day
day
treatment
despit
normal
ncv
day
repeat
ncv
day
show
moder
sever
neuropathi
sensori
sural
nerv
test
show
lack
action
potenti
distal
proxim
sensori
nerv
classifi
probabl
relat
studi
medic
thu
patient
withdrawn
studi
anoth
patient
receiv
daptomycin
mgkg
qd
day
studi
bsbmcavaebsbewavag
skin
skinstructur
infect
also
show
reduct
ncv
day
compar
baselin
measur
day
treatment
unlik
previou
case
patient
asyrnptornat
discontinu
studi
medic
neither
patient
return
followup
although
result
discontinu
studi
medic
neurolog
chang
classifi
seriou
ae
also
seen
select
number
patient
r
phase
ii
studi
patient
develop
bell
palsi
facial
palsi
receiv
daptomycin
patient
discontinu
studi
medic
one
addit
patient
also
show
reduct
ncv
phase
ii
studi
two
patient
phase
iii
studi
also
develop
paresthesia
howev
despit
fact
occurr
neuropathi
cranial
neuropathi
chang
ncv
suggest
daptomycin
use
may
associ
neuropath
neurolog
toxic
differ
rate
occurr
found
daptomycinand
cornparatortr
group
reason
discontinu
studi
medic
includ
diarrhea
acut
respiratori
insuffici
lead
coma
sever
respiratori
failur
elev
cardiac
enzym
patient
particip
phase
iii
trial
treatment
cap
r
patient
requir
discontinu
studi
medic
event
list
among
seriou
ae
possibl
probabl
relat
studi
medic
phase
ii
iii
studi
yet
lead
discontinu
daptomycin
cholecyst
leukopenia
pericardi
effus
complet
atrioventricular
block
acut
renal
failur
thrombocytopenia
hypersensit
reaction
eosinophilia
occur
patient
twentyeight
patient
also
experienc
ae
gastrointestin
system
death
phase
ii
iii
studi
attribut
daptomycin
studi
medic
howev
patient
receiv
daptomycin
complic
urinari
tract
infect
develop
worsen
atrial
fibril
complet
heart
block
despit
medic
histori
arrhythmia
daptomycin
use
could
exclud
possibl
factor
patient
death
nr
incid
ae
occur
patient
studi
list
tabl
vi
differ
incid
ae
treatment
group
earli
studi
suggest
rnyopathi
muscl
damag
might
concern
cpk
level
measur
baselin
treatment
complet
therapi
signific
differ
seen
cpk
level
incid
cpk
elev
among
patient
receiv
daptomycin
compar
treatment
two
patient
daptomycin
group
discontinu
treatment
day
therapi
elev
cpk
level
patient
symptomat
previous
describ
muscl
symptom
resolv
hour
cpk
elev
return
within
normal
limit
followup
period
studi
pool
laboratori
data
show
differ
hematolog
paramet
blood
chemistri
hepatobiliari
function
treatment
groupslit
despit
preclin
data
rat
suggest
dosedepend
revers
elev
marker
nephrotox
eg
excret
urinari
tubular
cell
malat
dehydrogenas
electron
microscopi
find
partial
loss
renal
brushbord
cell
proxim
tubul
review
safeti
data
clinic
studi
confirm
daptomycin
use
may
associ
renal
toxic
patient
complic
skin
skinstructur
infect
studi
show
increas
total
bilirubin
time
upper
limit
normallr
maximum
alanin
aminotransferas
alt
level
note
ul
maximum
aspart
aminotransferas
ast
ul
although
hepatotox
elev
liver
function
test
result
characterist
aff
associ
daptomycin
use
clinic
trial
hivposit
femal
patient
receiv
daptomycin
mgkg
bid
aureu
endocard
experienc
elev
liver
enzym
alt
ul
ast
ul
third
week
treatrnent
two
week
discontinu
daptornycin
enzym
level
began
declin
complet
resolut
seen
week
nr
overal
data
daptomycin
safeti
mgkg
qd
day
treatment
show
differ
daptomycin
compar
antimicrobi
therapi
l
r
skelet
muscl
toxic
chief
concern
regard
safeti
daptomycin
patient
monitor
symptom
muscl
pain
weak
especi
distal
extrem
manufactur
also
recommend
cpk
level
assess
weekli
daptomycin
use
although
small
studi
n
reveal
neuropath
cardiac
chang
electrocardiogram
daptomycin
mgkg
qd
day
patient
receiv
daptomycin
dose
anoth
studi
develop
sever
acut
respiratori
syndrom
subsequ
acut
renal
failur
possibl
relat
studi
medic
xlr
current
data
use
higher
dose
daptomycin
use
daptomycin
longer
durat
treatment
limit
clinic
trial
continu
gather
inform
safeti
regimen
may
need
reassess
although
result
vitro
studi
suggest
daptomycin
inhibit
induc
cytochrom
isozym
studi
could
determin
whether
daptomycin
may
substrat
cyp
metabol
potenti
drug
interact
daptomycin
aztreonam
probenecid
warfarin
simvastatin
investig
healthi
adult
signific
differ
detect
c
x
auc
total
renal
clearanc
daptomycin
singl
dose
administ
among
healthi
adult
singl
dose
aztreonam
rag
similarli
differ
paramet
found
daptomycin
pharmacokinet
singl
dose
daptomycin
mgkg
administ
probenecid
rng
qid
dose
among
healthi
adult
addit
warfarin
mg
singl
dose
day
steadyst
concentr
daptomycin
mgkg
qd
administ
day
total
show
chang
pharmacokinet
daptomycin
warfarin
pharmacodynam
interact
among
volunt
coadministr
simvastatin
mgd
daptomycin
mgkg
qd
day
also
show
pharmacokinet
differ
plasma
trough
concentr
either
drug
among
adult
age
year
studi
cpk
concentr
remain
within
upper
limit
normal
ul
male
ul
femal
throughout
studi
due
potenti
skelet
muscl
toxic
may
result
pharmacodynam
interact
phase
iii
studi
attempt
exclud
patient
receiv
daptomycin
coenzym
hmgcoa
reductas
inhibitor
ie
statin
simultan
howev
patient
receiv
statin
fibrat
daptomycin
signific
differ
cpx
elev
seen
patient
receiv
daptomycin
without
antihyperlipidem
agent
lxr
overal
although
dosag
adjust
may
suggest
temporari
suspens
hmgcoa
reductas
inhibitor
may
consid
treatment
daptomycin
due
concern
regard
myopathi
treatment
complic
skin
skinstructur
infect
daptomycin
administ
mgkg
qd
adult
data
collect
establish
efficaci
safeti
higher
dose
daptornycin
howev
studi
base
result
pharmacokinet
studi
dosag
adjust
recommend
older
age
year
obes
bmi
kgm
patient
similarli
dosag
adjust
daptomycin
recommend
treatment
mild
moder
hepat
impair
howev
use
pharmacokinet
daptomycin
specif
assess
among
patient
sever
hepat
impair
child
ugh
class
c
among
special
popul
pharmacokinet
may
affect
diseas
state
patient
renal
insuffici
may
requir
dosag
adjust
daptornycin
describ
pharmacokinet
section
patient
rnumin
receiv
hernodialysi
periton
dialysi
show
greater
accumul
daptornycin
measur
auc
patient
normal
renal
function
reduct
mean
clearanc
rate
suggest
daptornycin
dose
interv
extend
daptomycin
mgkg
q
h
patient
mumin
includ
patient
receiv
hemodialysi
continu
ambulatori
periton
dialysi
patient
undergo
dialysi
daptomycin
administ
complet
hemodialysi
therapi
day
daptomycin
classifi
pregnanc
categori
b
studi
rat
rabbit
dose
mgkg
reveal
harm
fetu
howev
adequ
wellcontrol
studi
conduct
pregnant
women
degre
daptornycin
excret
human
milk
known
thu
daptomycin
use
caution
pregnanc
lactat
clinic
pharmacokinet
studi
date
conduct
patient
age
year
efficaci
safeti
daptomycin
use
patient
age
year
also
establish
daptornycin
avail
singleus
vial
contain
mg
daptomycin
steril
lyophil
pale
yellow
light
brown
powder
everi
rag
daptomycin
reconstitut
ml
sodium
chlorid
inject
reconstitut
solut
dilut
sodium
chlorid
inject
deliv
iv
infus
minut
reconstimt
dilut
conduct
use
asept
techniqu
vial
contain
preserv
bacteriostat
agent
reconstitut
solut
stabl
hour
room
temperarar
hour
refriger
vial
dilut
solut
stabl
infus
bag
durat
room
temperatur
refriger
respect
howev
total
durat
time
vial
bag
exceed
hour
room
temperatur
hour
refriger
daptomycin
also
compat
lactat
ringer
solut
inj
ection
dextrosecontain
diluent
simultan
administr
iv
medic
recommend
limit
compat
data
collect
daptomycin
linezolid
quinupristindalfopristin
develop
treat
resist
gramposit
bacteri
infect
base
averag
wholesal
price
us
dollar
acquisit
cost
cours
daptomycin
therapi
mgkg
daili
vial
x
compar
iv
linezolid
mg
bid
vial
consider
expens
vancomycin
g
bid
vial
comparison
cost
treatment
cours
quinupristindalfopristin
mgkg
bid
vial
rel
long
halflif
hour
daptomycin
administ
qd
conveni
patient
health
care
worker
date
pharmacoeconom
analys
daptomycin
publish
high
acquisit
cost
daptomycin
reserv
infect
due
vancornycinresist
pathogen
infect
caus
gramposit
pathogen
fail
respond
vancomycin
therapi
daptomycin
first
member
new
class
antirnicrobi
agent
known
cyclic
lipopeptid
caus
rapid
cell
death
disrupt
multipi
function
aspect
bacteri
plasma
membran
pharmacolog
target
uniqu
among
current
avail
antimicrobi
agent
uniqu
mechan
action
crossresist
antibacteri
class
unlik
report
incid
spontan
resist
daptomycin
rare
subject
receiv
daptomycin
phase
iiiii
clinic
trial
confirm
case
emerg
resist
daptomycin
report
vitro
daptomycin
exhibit
rapid
bactericid
activ
wide
rang
clinic
import
gramposit
pathogen
includ
resist
strain
orsa
visa
vrsa
penicillinresist
pneumonia
vree
bactericid
activ
daptomycin
appear
independ
metabol
statu
bacteria
ie
activ
divid
stationari
bacteria
make
attract
choic
treatment
sequest
high
inoculum
infect
endocard
efficaci
data
pivot
trial
involv
total
subject
shown
daptomycin
efficaci
vancomycin
semisynthet
penicillin
ie
nakillin
oxacillin
dicloxacillin
flucloxacillin
treatment
complic
skin
soft
tissu
infect
daptomycin
vs
compar
drug
vs
studi
vs
studi
clinic
trial
evalu
efficaci
toler
daptomycin
dosag
mgkg
qd
staphylococc
bacteremia
endocard
ongo
although
incid
cpk
elev
observ
patient
treat
daptomycin
compar
drug
clinic
statist
differ
phase
iii
clinic
trialsj
lr
daptomycininduc
myopathi
alway
concern
earli
clinic
trial
subject
receiv
daptomycin
dosag
mgkg
iv
bid
develop
myopathi
day
respect
dose
daptomycininduc
myopathi
mild
nonprogress
skelet
muscl
specif
readili
revers
anim
model
oleson
et
al
report
daptomycinrel
musculoskelet
effect
could
minim
qd
administr
allow
time
dose
repair
subclin
damag
whether
daptomycininduc
myopathi
human
could
truli
curtail
qd
administr
remain
unknown
complic
skin
soft
tissu
infect
typic
treat
day
studi
need
delin
longterm
ae
human
musculoskelet
system
would
prudent
monitor
patient
muscl
pain
weak
obtain
cpk
level
weekli
undergo
daptomycin
therapi
medic
similar
musclerel
ae
hmgcoa
reductas
inhibitor
also
temporarili
discontinu
clinic
possibl
daptomycin
highli
protein
bound
primarili
albumin
theoret
high
degre
protein
bind
lead
low
level
free
activ
drug
suggest
clinic
failur
daptomycin
lead
studi
suspens
earli
part
attribut
high
degre
protein
bind
although
subject
administ
rel
low
dosag
daptomycin
mgkg
daili
treatment
bacteremia
endocarditisj
clinic
relev
protein
bind
daptomycin
therapi
remain
elucid
despit
concern
daptomycin
remain
use
addit
antimicrobi
armamentarium
daptomycin
reserv
lifethreaten
situat
andor
multidrugresist
pathogen
suspect
identifi
efficaci
resist
pathogen
preserv
rapid
bactericid
activ
uniqu
mechan
action
low
incid
resist
lack
crossresist
antimicrobi
agent
daptomycin
may
use
treatment
complic
skin
skinstructur
infect
also
sequest
highinoculum
infect
eg
endocard
due
resist
gramposit
pathogen
howev
use
daptomycin
beyond
day
dose
mgkg
qd
recommend
clinic
efficaci
safeti
data
becom
avail
